AUDUBON, PA — Globus Medical, Inc. (NYSE: GMED) reported a double-digit top-line increase and higher profitability for the quarter ended September 30, 2025, citing U.S. spine momentum, better margins, and contributions from its Nevro acquisition. Worldwide net sales were $769.0 million, up 22.9% year over year (22.3% constant currency). Base business, excluding Nevro, net sales were $669.8 million, up 7.0%. U.S. revenue rose 24.6%; international revenue increased 16.5% as reported and 13.5% in constant currency.
GAAP net income was $119.0 million, up 129.5% from the prior-year quarter. GAAP diluted EPS was $0.88 versus $0.38 a year ago; non-GAAP diluted EPS was $1.18, up 42.6%. Net cash provided by operating activities was $249.7 million, and non-GAAP free cash flow was a record $213.9 million. The company repurchased $40 million of shares in the quarter, bringing year-to-date repurchases to $255.5 million.
“We are pleased with the strength of our overall results and continued progress throughout the company,” commented Keith Pfeil, President and Chief Executive Officer. “Q3 revenue rose 23%, driven by 10% growth in our US Spine business, as momentum accelerated during the quarter with broad based demand across our products and geographies. Our recently acquired Nevro business continued to exceed expectations, underscoring the strength of our integration strategy, as we position this business for future growth. Strength in revenue translated into enhanced earnings and profitability, with meaningful improvements in adjusted gross margins and operating expenses, reflecting both synergy capture and operating leverage from the NuVasive merger and Nevro acquisition. Looking ahead, we remain focused on finishing 2025 strong, with a clear path toward consistent organic growth through innovation, disciplined execution and delivering differentiated technologies that improve patient outcomes.”
“Our third quarter results highlight our ability to balance growth with operational efficiency and synergy execution. We achieved record non-GAAP free cash flow of $213.9 million in the quarter, up 24% quarter-over-quarter and non-GAAP diluted earnings per share of $1.18, growing 43% compared to the prior year quarter,” commented Kyle Kline, Chief Financial Officer. “We’ve executed share repurchases of $40 million this past quarter, bringing our total repurchases to $255.5 million through the first nine months of 2025, further demonstrating our confidence in the business and our commitment to creating long-term value for our shareholders.”
On guidance, Globus lifted its 2025 revenue outlook to $2.86–$2.90 billion (from $2.80–$2.90 billion) and raised its non-GAAP fully diluted EPS range to $3.75–$3.85 (from $3.00–$3.30). The company now expects the Nevro acquisition to be accretive to 2025 earnings.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.